NCT06961344
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
Active, Not Recruiting
PHASE2All AgesInterventionalTreatmentTisento Therapeutics
~44 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:zagociguat 15mg
At a glance
Recruiting sites
0 of 16 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment-emergent Adverse Events (TEAEs)
Measured over Day 1 through the Follow-up for treatment period 4 weeks after last dose of study medication.
Conditions
Where it's being run
16 sites across 13 statesTexas2
Italy2
United Kingdom2
California1
Colorado1
Georgia1
Massachusetts1
New York1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence of Treatment-emergent Adverse Events (TEAEs)Day 1 through the Follow-up for treatment period 4 weeks after last dose of study medication.
TEAEs are any untoward event that may or may not be related to study medication.